Evolution Infographic – An Analysis of 2015 Therapeutic IPOs

In the first half of 2015 fifty therapeutics companies finalised their IPOs, raising over $5.17 billion across multiple global exchanges. Evolution Global Talent Attraction analysed the therapeutic targets and IPO

Evolution Infographic – An Analysis of Biopharmaceutical Production in EMEA

Evolution Global Talent Attraction’s latest market research report looks at the capacity and content of biopharmaceutical production in Europe, the Middle East and Africa. Rather than publish a lengthy report,

Record-setting IPO for cancer immunotherapy company NantKwest

NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer,

Charles River Labs to Acquire Rapid Bacterial Detection System Provider Celsis International

Preclinical CRO Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject

Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies

Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will leverage T cell therapeutic

Genentech and Regeneron win Thomson Reuters Allicense Awards for Top BioPharma Deals of the Year

The Intellectual Property and Science business of Thomson Reuters recently honoured Genentech Partnering and Seragon, and Regeneron and Avalanche with the Allicense 2015 Breakthrough Award for Deals of the Year.

Merck Millipore Acquire Exclusive Rights to Singulex Single Molecule Counting Technology

Merck Millipore and Singulex, the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, have announced that they have entered into a definitive

Kite Pharma & bluebird bio Announce Strategic Collaboration to Treat HPV-Associated Cancers

With the Cancer Immunotherapy market forecast to increase to $9 billion by 2022, it’s no surprise that the burgeoning sector has attracted the attention of biotech and pharma investors across

Merck Acquisition of Sigma-Aldrich receives conditional clearance from European Commission

Sigma-Aldrich’s acquisition by Merck has been conditionally cleared by the European Commission, and has received full clearance from the Chinese Ministry of Commerce. Merck and Sigma have already cleared from

Evolution Global Talent Attraction featured on GEN JobWatch

Evolution founder and Managing Director Dr. Jason Beckwith was recently featured on monthly Genetic Engineering & Biotechnology News column JobWatch. Dr. Beckwith offered GEN an insight into the hiring practices

Merck appoints Udit Batra to head combined life science business ahead of Sigma-Aldrich acquisition

Udit Batra has been appointed to lead the combined life science business of Merck Millipore and Sigma-Aldrich once the acquisition of Sigma-Aldrich has been successfully completed later this year. Udit

Bio-Rad Reports Strong Fourth-Quarter and Full-Year 2014 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended

Merck, Sanofi, Syngenta & GSK announce full year results for 2014

Pharma giants Merck, Sanofi & GSK announced their full-year results for 2014 this week, as did global AgroChemical multinational Syngenta. Syngenta reported sales of $15.1 billion USD, achieving their integrates

Thermo Fisher Strengthens Bioproduction Offering by Acquiring Advanced Scientifics

Thermo Fisher Scientific have announced their acquisition of ASI (Advanced Scientifics, Inc.) for a cash payment of $300 million USD as the company seeks to strengthen their bioproduction offerings. ASI

Teixobactin Discovery Heralded as an Antibiotic Game Changer

Up until now uncultured bacteria have been an untapped source of new antibiotics, but promising research published in Nature yesterday highlights novel in-situ methods for growing uncultured microorganisms. One of